The deal for AMO, announced in September 2016, includes its portfolio of ophthalmic products covering cataract surgery, laser refractive surgery and consumer eye health. The business posts annual sales of $1.1 billion and is slated to be folded into the medical devices segment as a separate platform within J&J Vision Care.
“With the addition of AMO’s world-renowned ophthalmic surgery business, J&J Vision is poised to become a world leader in eye health,” chairwoman Ashley McEvoy said in a press release. “Sight is precious, it’s the sense people fear losing the most. By bringing on board surgical solutions that are supported by the resources and global reach of Johnson & Johnson, we can improve and restore sight for more patients across the globe.”
New Brunswick, N.J.-based Johnson & Johnson has said it expects the acquisition to be “modestly accretive immediately to adjusted earnings per share.”
Early rates for DeviceTalks Boston end August 15th.
Don't miss the chance to save $100 and join top medtech innovators including leaders from Hologic, Google, Gray Matter, TransEnterix, NxStage Medical, Smith & Nephew, HeartFlow, Dynatronics, Johnson & Johnson, Allied Minds, and many more.
View Full Agenda
Register today to save. Use code LASTCALL to save an additional 10%.